ARIAD Pharmaceuticals (ARIA) Form 4 ARIAD PHARMACEUTICALS / Massimo Radaelli ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Radaelli Massimo

(Last) (First) (Middle)

C/O ARIAD PHARMACEUTICALS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARIAD PHARMACEUTICALS INC [ ARIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2016		M(1)		22,588	A	$1.35	128,088	D
Common Stock	06/10/2016		S(1)		22,588	D	$8.3	105,500	D
Common Stock	06/13/2016		M(1)		27,319	A	$6.38	132,819	D
Common Stock	06/13/2016		M(1)		2,412	A	$1.35	135,231	D
Common Stock	06/13/2016		M(1)		25,000	A	$7.39	160,231	D
Common Stock	06/13/2016		M(1)		25,000	A	$6.45	185,231	D
Common Stock	06/13/2016		S(1)		79,731	D	$8.2505(2)	105,500	D
Common Stock	06/14/2016		M(1)		6,250	A	$4.91	111,750	D
Common Stock	06/14/2016		S(1)		6,250	D	$8.1334(3)	105,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.35	06/10/2016		M			22,588	10/10/2009(4)	10/10/2018(5)	Common Stock	22,588	$1.35	2,412	D
Stock Option (Right to Buy)	$6.38	06/13/2016		M			27,319	01/31/2011(6)	01/31/2021(5)	Common Stock	27,319	$6.375	0	D
Stock Option (Right to Buy)	$1.35	06/13/2016		M			2,412	10/10/2009(4)	10/10/2018(5)	Common Stock	2,412	$1.35	0	D
Stock Option (Right to Buy)	$7.39	06/13/2016		M			25,000	03/31/2014(7)	01/31/2024(5)	Common Stock	25,000	$7.39	0	D
Stock Option (Right to Buy)	$6.45	06/13/2016		M			25,000	03/31/2015(8)	01/31/2025(5)	Common Stock	25,000	$6.45	0	D
Stock Option (Right to Buy)	$4.91	06/14/2016		M			6,250	03/31/2016(9)	02/01/2026(5)	Common Stock	6,250	$4.91	18,750	D

Explanation of Responses:

1. The shares were acquired and sold upon exercise of stock options that would have expired on October 21, 2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.2550, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.131 to $8.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.

4. The stock options were granted on 10/10/2008 and vested in three annual installments commencing on 10/10/2009.

5. The stock options would have expired on October 21, 2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.

6. The stock options were granted on 01/31/2011 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2011.

7. The stock options were granted on 01/31/2014 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2014.

8. The stock options were granted on 01/31/2015 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2015.

9. The stock options were granted on 02/01/2016 and vest as to one-fourth of the options in quarterly installments commencing on March 31, 2016.

Remarks:

	Karen E. Needham, under power of attorney dated 4/19/2016	06/14/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.